Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia

Haematologica. 2018 Jul;103(7):e307-e310. doi: 10.3324/haematol.2017.186908. Epub 2018 Feb 22.

Authors

Jorge J Castillo^{1

2}, Joshua N Gustine³, Kirsten Meid³, Toni Dubeau³, Patricia Severns³, Steven P Treon^{3

2}

Affiliations

¹ Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA jorgej_castillo@dfci.harvard.edu.
² Harvard Medical School, Boston, MA, USA.
³ Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA.

No abstract available

Publication types

Letter

MeSH terms

Adenine / analogs & derivatives
Antineoplastic Agents / administration & dosage*
Antineoplastic Agents / therapeutic use
Biomarkers
Humans
Piperidines
Protein Kinase Inhibitors / administration & dosage*
Protein Kinase Inhibitors / therapeutic use
Pyrazoles / administration & dosage*
Pyrazoles / therapeutic use
Pyrimidines / administration & dosage*
Pyrimidines / therapeutic use
Substance Withdrawal Syndrome / diagnosis
Substance Withdrawal Syndrome / etiology*
Waldenstrom Macroglobulinemia / complications*
Waldenstrom Macroglobulinemia / diagnosis
Waldenstrom Macroglobulinemia / drug therapy
Withholding Treatment*

Substances

Antineoplastic Agents
Biomarkers
Piperidines
Protein Kinase Inhibitors
Pyrazoles
Pyrimidines
ibrutinib
Adenine